| Title |
Ligand efficiency metrics considered harmful
|
|---|---|
| Published in |
Perspectives in Drug Discovery and Design, June 2014
|
| DOI | 10.1007/s10822-014-9757-8 |
| Pubmed ID | |
| Authors |
Peter W. Kenny, Andrei Leitão, Carlos A. Montanari |
| Abstract |
Ligand efficiency metrics are used in drug discovery to normalize biological activity or affinity with respect to physicochemical properties such as lipophilicity and molecular size. This Perspective provides an overview of ligand efficiency metrics and summarizes thermodynamics of protein-ligand binding. Different classes of ligand efficiency metric are critically examined and the study concludes with suggestions for alternative ways to account for physicochemical properties when prioritizing and optimizing leads. |
X Demographics
The data shown below were collected from the profiles of 10 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 3 | 30% |
| Denmark | 1 | 10% |
| Italy | 1 | 10% |
| United Kingdom | 1 | 10% |
| Netherlands | 1 | 10% |
| Unknown | 3 | 30% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Scientists | 6 | 60% |
| Members of the public | 4 | 40% |
Mendeley readers
The data shown below were compiled from readership statistics for 135 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 3 | 2% |
| United Kingdom | 2 | 1% |
| Norway | 1 | <1% |
| Brazil | 1 | <1% |
| Switzerland | 1 | <1% |
| India | 1 | <1% |
| Germany | 1 | <1% |
| Mexico | 1 | <1% |
| Sweden | 1 | <1% |
| Other | 0 | 0% |
| Unknown | 123 | 91% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 58 | 43% |
| Student > Ph. D. Student | 15 | 11% |
| Other | 8 | 6% |
| Student > Master | 8 | 6% |
| Professor | 7 | 5% |
| Other | 26 | 19% |
| Unknown | 13 | 10% |
| Readers by discipline | Count | As % |
|---|---|---|
| Chemistry | 61 | 45% |
| Agricultural and Biological Sciences | 20 | 15% |
| Biochemistry, Genetics and Molecular Biology | 14 | 10% |
| Pharmacology, Toxicology and Pharmaceutical Science | 10 | 7% |
| Medicine and Dentistry | 6 | 4% |
| Other | 7 | 5% |
| Unknown | 17 | 13% |
Attention Score in Context
This research output has an Altmetric Attention Score of 36. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 April 2022.
All research outputs
#1,133,828
of 25,457,858 outputs
Outputs from Perspectives in Drug Discovery and Design
#7
of 949 outputs
Outputs of similar age
#10,888
of 242,245 outputs
Outputs of similar age from Perspectives in Drug Discovery and Design
#2
of 15 outputs
Altmetric has tracked 25,457,858 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 95th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 949 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.3. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 242,245 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 95% of its contemporaries.
We're also able to compare this research output to 15 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 86% of its contemporaries.